News
Feed
Events
Feed
News
+ Events
Feed

CEVEC Pharmaceuticals GmbH

  • Land Deutschland

Aktuelle News

20 September 2022

14:00 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC Pharmaceuticals GmbH: ROKOTE Laboratories licenses CEVEC’s CAP® Ad Technology for vaccine manufacturing

13 Juli 2022

14:00 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients

7 September 2021

14:50 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC and UCB sign agreement for the use of CEVEC’s ELEVECTA(R) AAV manufacturing technology in Gene Therapy

27 Juli 2021

14:00 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

2 Februar 2021

14:00 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP(R) Technology in anti-tumor cell therapies

8 Januar 2021

12:00 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy

10 November 2020

14:00 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC signs agreement with Roche for the use of CEVEC’s ELEVECTA(R) Technology in gene therapy

19 Oktober 2020

13:00 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC AND RZNOMICS SIGN LICENSE AGREEMENT FOR THE USE OF CAP(R) TECHNOLOGY IN MANUFACTURING OF ADENOVIRAL VECTORS

28 April 2020

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC Announces the Launch of the ELEVECTA(R) Platform – the Stable Producer Cell Line Technology for AAV Gene Therapy Vectors

16 April 2020

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use

19 Dezember 2019

11:00 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC and CellGenix announce the launch of GMP-grade TGF-ß1 for cell and gene therapy applications

16 April 2019

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC closes major financing round to further expand and commercialize its viral vector manufacturing platform

28 Juni 2018

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC strengthens its Scientific Advisory Board with the appointment of gene therapy specialist J. Fraser Wright, Ph.D.

8 Mai 2018

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC’s proprietary CAP(R)Go technology

31 Januar 2018

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC and CellGenix cooperation leads to expansion of CellGenix cytokine portfolio with CAP(R)Go technology-derived TGF-ß1 for ex vivo cell culture

16 Januar 2018

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC to introduce new helper-free AAV packaging cell line for scalable stable gene therapy vector production at the Phacilitate Cell & Gene Therapy World Conference

14 November 2017

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC has been granted a new CAP(R)Go technology patent and reinforces its leading role in production of recombinant proteins previously out of reach

6 Juli 2017

09:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC licenses CAP(R)Go technology in the field of veterinary vaccines

11 Mai 2017

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production

16 März 2017

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC, medac and Provecs Medical enter into far-reaching adenoviral vector collaboration in oncology

9 Februar 2017

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC licenses CAP(R) technologies for the development and commercialization of vaccines against Zika Virus infections

27 Oktober 2016

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC submits Biologics Master File (BB-MF) for CAP(R) Technology to the U.S. FDA

29 Juni 2016

08:30 Corporate EN

CEVEC Pharmaceuticals GmbH

Corporate
EN

CEVEC further strengthens organization to drive industrialization and commercialization of CAP(R) technologies

6 Juni 2016

14:00 Corporate

CEVEC Pharmaceuticals GmbH

Corporate

CEVEC und Paragon Bioservices beschließen umfangreiche Kooperation zum Roll-out der CAP(R) Technologien in Nordamerika

10 Mai 2016

08:30 Corporate

CEVEC Pharmaceuticals GmbH

Corporate

CEVECs CAP(R)GT setzt mit RCA-freier Produktion von adenoviralen Vektoren neuen Standard für Gentherapie-Anwendungen

22 Februar 2016

10:00 Corporate

CEVEC Pharmaceuticals GmbH

Corporate

CEVEC intensiviert ihre Marketing Aktivitäten und präsentiert auf verschiedenen angesehenen wissenschaftlichen Konferenzen in Europa und den USA

20 Januar 2016

08:30 Corporate

CEVEC Pharmaceuticals GmbH

Corporate

CEVEC und das City of Hope Beckman-Forschungsinstitut unterzeichnen Kooperations- und Lizenzvereinbarung für CEVEC’s proprietäre CAP(R)GT Technologie

28 Oktober 2015

08:30 Corporate

CEVEC Pharmaceuticals GmbH

Corporate

CEVEC und BioLamina kombinieren Technologieführerschaft für die kommerzielle Produktion rekombinanter Laminine für ex vivo-Zelltherapien

14 Oktober 2015

08:30 Corporate

CEVEC Pharmaceuticals GmbH

Corporate

CEVEC stärkt Team zur Umsetzung seiner starken Wachstumsstrategie

7 Oktober 2015

08:30 Corporate

CEVEC Pharmaceuticals GmbH

Corporate

CEVEC und CellGenix unterzeichnen Kooperations- und Lizenzvereinbarung für CEVECs unternehmenseigene CAP(R)Go Technologie

Anstehende Events

Keine Events gefunden